FDA Highlights: Fenofibrate reduces cardiovascular events in type-2 diabetes, especially for women
by Bruce Sylvester: Fenofibrate treatment reduces cardiovascular disease risks in persons with type-2 diabetes, especially women, researchers reported on August 18 in Diabetologia.